Vanguard Group Inc. Sells 29,122 Shares of West Pharmaceutical Services Inc. (NYSE:WST)

Vanguard Group Inc. decreased its position in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 0.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,320,338 shares of the medical instruments supplier’s stock after selling 29,122 shares during the period. Vanguard Group Inc. owned approximately 9.93% of West Pharmaceutical Services worth $916,140,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Stephens Inc. AR grew its holdings in shares of West Pharmaceutical Services by 3.0% during the 2nd quarter. Stephens Inc. AR now owns 3,306 shares of the medical instruments supplier’s stock worth $414,000 after purchasing an additional 96 shares in the last quarter. Zions Bancorporation N.A. grew its holdings in shares of West Pharmaceutical Services by 3.0% during the 2nd quarter. Zions Bancorporation N.A. now owns 5,242 shares of the medical instruments supplier’s stock worth $656,000 after purchasing an additional 155 shares in the last quarter. Advisory Services Network LLC grew its holdings in shares of West Pharmaceutical Services by 84.5% during the 2nd quarter. Advisory Services Network LLC now owns 393 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 180 shares in the last quarter. GW Henssler & Associates Ltd. grew its holdings in shares of West Pharmaceutical Services by 6.8% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 2,900 shares of the medical instruments supplier’s stock worth $363,000 after purchasing an additional 184 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of West Pharmaceutical Services by 4.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,454 shares of the medical instruments supplier’s stock worth $557,000 after purchasing an additional 187 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Several analysts have recently issued reports on the company. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $158.00 target price on the stock in a report on Saturday, August 3rd. Bank of America raised West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a report on Friday, July 26th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $130.72.



Shares of WST traded up $0.16 during trading hours on Tuesday, hitting $144.06. 19,224 shares of the company were exchanged, compared to its average volume of 307,116. The firm’s fifty day moving average is $144.12 and its 200 day moving average is $124.45. The company has a market cap of $10.55 billion, a price-to-earnings ratio of 51.22, a P/E/G ratio of 4.07 and a beta of 1.27. The company has a quick ratio of 2.27, a current ratio of 3.02 and a debt-to-equity ratio of 0.18. West Pharmaceutical Services Inc. has a fifty-two week low of $91.75 and a fifty-two week high of $152.10.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.17. The business had revenue of $469.70 million for the quarter, compared to analyst estimates of $459.90 million. West Pharmaceutical Services had a return on equity of 16.93% and a net margin of 12.94%. West Pharmaceutical Services’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the firm posted $0.70 earnings per share. Analysts anticipate that West Pharmaceutical Services Inc. will post 3.07 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 6th. Investors of record on Wednesday, October 23rd will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.42%. The ex-dividend date is Tuesday, October 22nd. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.35%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: What is Put Option Volume?

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.